Pharmacokinetics/pharmacodynamics of L‐ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes
Abstract Hepatic encephalopathy (HE) is a serious neurocognitive complication of liver dysfunction, often associated with elevated plasma ammonia. Ornithine phenylacetate (OP), a potent ammonia scavenger, is being evaluated for the treatment of acute/overt HE. The pharmacokinetics and pharmacodynamics of OP in patients with HE were characterized in this phase IIb study (NCT01966419). Adult patients hospitalized with an overt HE episode, cirrhosis, and plasma ammonia above the upper limit of normal (ULN) who failed to improve after 48 hours’ standard care were randomly assigned to continuous intravenous OP (10, 15, or 20 g/day, based on Child–Turcotte–Pugh score) or matching placebo for 5 days. Plasma levels of ornithine and phenylacetic acid (PAA) and plasma/urinary levels of phenylacetylglutamine (PAGN) (primary metabolite of PAA) were regularly assessed; plasma ammonia level was the primary pharmacodynamic variable. PAA demonstrated dose‐dependent pharmacokinetics; ornithine and PAGN levels increased with dose. PAGN urinary excretion represented ~50%–60% of administered PAA across all doses. Mean reduction in plasma ammonia with OP at 3 hours postinfusion was significantly greater versus placebo ( p = 0.014); and time to achieve plasma ammonia less than or equal to the ULN was significantly reduced ( p = 0.028). Achievement of clinical response based on HE stage was associated with a greater reduction in mean plasma ammonia level ( p = 0.009). OP effects on plasma ammonia were consistent with its proposed mechanism of action as a primary ammonia scavenger, with a significant association between reduced plasma ammonia and improvement in HE stage. OP should be further evaluated as a promising treatment for hyperammonemia in patients with overt HE..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Clinical and Translational Science - 15(2022), 6, Seite 1449-1459 |
| Beteiligte Personen: |
Safadi, Rifaat [VerfasserIn] |
|---|
| Anmerkungen: |
© 2022 ASCPT. |
|---|
| Umfang: |
11 |
|---|
| doi: |
10.1111/cts.13257 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY004405803 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY004405803 | ||
| 003 | DE-627 | ||
| 005 | 20230307135359.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230214s2022 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/cts.13257 |2 doi | |
| 028 | 5 | 2 | |a CTS_CTS13257.xml |
| 035 | |a (DE-627)WLY004405803 | ||
| 035 | |a (WILEY)CTS13257 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 100 | 1 | |a Safadi, Rifaat |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacokinetics/pharmacodynamics of L‐ornithine phenylacetate in overt hepatic encephalopathy and the effect of plasma ammonia concentration reduction on clinical outcomes |
| 264 | 1 | |c 2022 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2022 ASCPT. | ||
| 520 | |a Abstract Hepatic encephalopathy (HE) is a serious neurocognitive complication of liver dysfunction, often associated with elevated plasma ammonia. Ornithine phenylacetate (OP), a potent ammonia scavenger, is being evaluated for the treatment of acute/overt HE. The pharmacokinetics and pharmacodynamics of OP in patients with HE were characterized in this phase IIb study (NCT01966419). Adult patients hospitalized with an overt HE episode, cirrhosis, and plasma ammonia above the upper limit of normal (ULN) who failed to improve after 48 hours’ standard care were randomly assigned to continuous intravenous OP (10, 15, or 20 g/day, based on Child–Turcotte–Pugh score) or matching placebo for 5 days. Plasma levels of ornithine and phenylacetic acid (PAA) and plasma/urinary levels of phenylacetylglutamine (PAGN) (primary metabolite of PAA) were regularly assessed; plasma ammonia level was the primary pharmacodynamic variable. PAA demonstrated dose‐dependent pharmacokinetics; ornithine and PAGN levels increased with dose. PAGN urinary excretion represented ~50%–60% of administered PAA across all doses. Mean reduction in plasma ammonia with OP at 3 hours postinfusion was significantly greater versus placebo ( p = 0.014); and time to achieve plasma ammonia less than or equal to the ULN was significantly reduced ( p = 0.028). Achievement of clinical response based on HE stage was associated with a greater reduction in mean plasma ammonia level ( p = 0.009). OP effects on plasma ammonia were consistent with its proposed mechanism of action as a primary ammonia scavenger, with a significant association between reduced plasma ammonia and improvement in HE stage. OP should be further evaluated as a promising treatment for hyperammonemia in patients with overt HE. | ||
| 700 | 1 | |a Rahimi, Robert S. |4 aut | |
| 700 | 1 | |a Thabut, Dominique |4 aut | |
| 700 | 1 | |a Bajaj, Jasmohan S. |4 aut | |
| 700 | 1 | |a Ram Bhamidimarri, Kalyan |4 aut | |
| 700 | 1 | |a Pyrsopoulos, Nikolaos |4 aut | |
| 700 | 1 | |a Potthoff, Amy |4 aut | |
| 700 | 1 | |a Bukofzer, Stan |4 aut | |
| 700 | 1 | |a Wang, Laurene |4 aut | |
| 700 | 1 | |a Jamil, Khurram |4 aut | |
| 700 | 1 | |a Devarakonda, Krishna R. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and Translational Science |g 15(2022), 6, Seite 1449-1459 |w (DE-627)WLY004400259 |x 17528062 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2022 |g number:6 |g pages:1449-1459 |g extent:11 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2022 |e 6 |h 1449-1459 |g 11 | ||